In contrast, this dendritic cell-based immunotherapy aims to induce a new, specific immune response against the tumor." Describing the strategy, study co-supervisor Stefanie Wculek—formerly at ...

Results from a phase 1 trial showed the independently reviewed best overall objective response rate was 71% in emactuzumab-treated patients. The Food and Drug Administration (FDA) has granted Fast ...

and cancer cells, providing insights into how fibroblast activation can influence tumor progression. The model opens up new possibilities for studying fibroblast-driven effects in diverse settings, ...

Singapore Institute of Molecular and Cell Biology, Agency for Science, Technology, and Research (A*STAR), 61 Biopolis Drive, Proteos, Singapore 138673, Singapore Department of Diagnostic Radiology, ...

Imagine a super-charged immune cell that can launch a focused attack on stubborn solid tumors — a smart fighter that destroys cancer cells for days without tiring. USC biomedical engineers have ...

The company also develops Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer; and mirdametinib ...

1Department of Gynecologic Oncology, University Medical Center Utrecht, Utrecht, the Netherlands. *Corresponding Author: Geertruid J. Brink, Department of Gynecologic Oncology, University Medical ...